Kaplan-Meier Plotter analysis revealed that lower FGL1 expression correlated with longer OS in patients undergoing anti-PD1 therapy, including those with bladder cancer, glioblastoma, and melanoma (Figure 6B). Here, FGL1 is linked to urinary bladder carcinoma.